Pernix completes $102m acquisitions of Cypress and Hawthorn
This article was originally published in Scrip
Executive Summary
Pernix Therapeutics has now completed the acquisition of the privately-owned firms, Cypress Pharmaceuticals (a generic drugs company) and Hawthorn Pharmaceuticals (a branded pharmaceutical company).